Deenova S.r.l.

Based in Italy, Deenova S. r. l. specializes in pharmacy automation solutions that enhance medication management and logistics processes within healthcare facilities.

Deenova S. r. l. , founded in 2015, develops automation technology for healthcare providers.

The company is headquartered in Italy and serves clients across Europe. The CEO, Giorgio Pavesi, brings extensive experience in the sector. Deenova was involved in 2 deals, with the most recent in November 2024 when Ersel Asset Management and Amundi acquired it from H. I.

G. Capital. Deenova specializes in pharmacy automation solutions designed to streamline logistics processes within healthcare facilities. Their core offerings include a range of products developed for enhanced medication management and dispensing, such as the D1 Series, which encompasses the ORBIT E-Prescribing software, ALL-IN-1 personalized medication dispensing stations, and comprehensive medicines administration trolleys.

Additionally, the D3 Series provides unit dose repackaging and storage solutions, while the D8 Series focuses on medical device traceability. The solutions are tailored to meet the specific workflow requirements of healthcare providers, including pharmacists and nurses, thereby maximizing operational efficiency. The company primarily serves clients across Europe, including notable institutions such as University Hospitals of Leicester, ASL Alessandria, and Policlinico San Martino in Genova. In 2023, Deenova reported a revenue of USD 23.

30 mn and an EBITDA of USD 2. 99 mn. The company's revenue structure is primarily driven by direct sales and service agreements with healthcare institutions. Deenova operates a B2B model, providing automation solutions under contract terms that include one-time purchases and multi-year agreements for services and support.

Revenue generation also includes subscriptions for their software solutions, ensuring updates and maintenance, and sales of hardware products like the ALL-IN-1 dispensing units. Transactions typically occur through negotiated contracts, which may involve customized pricing plans based on the healthcare facility’s needs, with an established client base across various hospitals and healthcare systems in Europe. Following the acquisition in November 2024, Deenova plans to enhance its capabilities and strengthen its market presence in the healthcare sector. The company aims to develop and launch new products in the pharmacy automation space, although specific release dates are not disclosed.

Furthermore, Deenova targets expansion into new geographic markets, with plans to reach additional regions by late 2025. The recent funding will support these initiatives, bolstering their operational capabilities and marketing efforts to facilitate growth.